<DOC>
	<DOC>NCT01218386</DOC>
	<brief_summary>The present study is set up to evaluate the efficacy of a programmation by administration of estrogen valerate during 6 or more consecutive days. In this prospective randomised trial, we study the impact of administration of Progynova® during 6, 7,8 9 or 10 consecutive days during the luteo-follicular transition period of the menstrual cycle.</brief_summary>
	<brief_title>Pretreatment With Estradiol Valerate</brief_title>
	<detailed_description>See Section Interventions</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>&lt; 36 years old on day of randomisation FSH &lt; 12 (in the early follicular phase) Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation. Regular menstrual cycles of 2135 days, presumed to be ovulatory. BMI between 18 and 29 (both inclusive) 1st or 2nd trial IVF or ICSI ≥ 36 years old on day of randomisation Endometriosis ≥ grade 3 PCOS Poor responders (development of &lt; 4 follicles in a previous IVF/ICSI cycle) Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>ICSI</keyword>
	<keyword>GnRH antagonists</keyword>
	<keyword>planning</keyword>
</DOC>